Mastronarde John G, Anthonisen Nicholas R, Castro Mario, Holbrook Janet T, Leone Frank T, Teague W Gerald, Wise Robert A
N Engl J Med. 2009 Apr 9;360(15):1487-99. doi: 10.1056/NEJMoa0806290.
Gastroesophageal reflux is common among patients with asthma but often causes mild or no symptoms. It is not known whether treatment of gastroesophageal reflux with proton-pump inhibitors in patients who have poorly controlled asthma without symptoms of gastroesophageal reflux can substantially improve asthma control.
In a parallel-group, double-blind trial, we randomly assigned 412 participants with inadequately controlled asthma, despite treatment with inhaled corticosteroids, and with minimal or no symptoms of gastroesophageal reflux to receive either 40 mg of esomeprazole twice a day or matching placebo. Participants were followed for 24 weeks with the use of daily asthma diaries, spirometry performed once every 4 weeks, and questionnaires that asked about asthma symptoms. We used ambulatory pH monitoring to ascertain the presence or absence of gastroesophageal reflux in the participants. The primary outcome was the rate of episodes of poor asthma control, as assessed on the basis of entries in asthma diaries.
Episodes of poor asthma control occurred with similar frequency in the placebo and esomeprazole groups (2.3 and 2.5 events per person-year, respectively; P=0.66). There was no treatment effect with respect to individual components of the episodes of poor asthma control or with respect to secondary outcomes, including pulmonary function, airway reactivity, asthma control, symptom scores, nocturnal awakening, or quality of life. The presence of gastroesophageal reflux, which was documented by pH monitoring in 40% of participants with minimal or no symptoms, did not identify a subgroup of patients that benefited from treatment with proton-pump inhibitors. There were fewer serious adverse events among patients receiving esomeprazole than among those receiving placebo (11 vs. 17).
Despite a high prevalence of asymptomatic gastroesophageal reflux among patients with poorly controlled asthma, treatment with proton-pump inhibitors does not improve asthma control. Asymptomatic gastroesophageal reflux is not a likely cause of poorly controlled asthma. (ClinicalTrials.gov number, NCT00069823.)
胃食管反流在哮喘患者中很常见,但通常引起轻微症状或无症状。对于没有胃食管反流症状但哮喘控制不佳的患者,使用质子泵抑制剂治疗胃食管反流是否能显著改善哮喘控制尚不清楚。
在一项平行组双盲试验中,我们将412名尽管使用吸入性糖皮质激素治疗但哮喘仍控制不佳且有轻微或无胃食管反流症状的参与者随机分为两组,分别接受每日两次40毫克埃索美拉唑或匹配的安慰剂治疗。使用每日哮喘日记、每4周进行一次的肺功能测定以及询问哮喘症状的问卷对参与者进行24周的随访。我们使用动态pH监测来确定参与者是否存在胃食管反流。主要结局是根据哮喘日记中的记录评估的哮喘控制不佳发作率。
安慰剂组和埃索美拉唑组哮喘控制不佳发作的频率相似(分别为每人每年2.3次和2.5次事件;P = 0.66)。在哮喘控制不佳发作的各个组成部分或包括肺功能、气道反应性、哮喘控制、症状评分、夜间觉醒或生活质量在内的次要结局方面,均未发现治疗效果。40%有轻微或无症状的参与者通过pH监测记录到存在胃食管反流,但这并未识别出能从质子泵抑制剂治疗中获益的患者亚组。接受埃索美拉唑治疗的患者严重不良事件少于接受安慰剂治疗的患者(分别为11例和17例)。
尽管哮喘控制不佳的患者中无症状胃食管反流的患病率很高,但使用质子泵抑制剂治疗并不能改善哮喘控制。无症状胃食管反流不太可能是哮喘控制不佳的原因。(临床试验注册号,NCT00069823。)